Q-omics provides the consensus-scored CEP20 profile across patient tissues and cancer cell-line models. CEP20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, CEP20 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CEP20 protein abundance shows 35,431 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SCLC, KIRC, and PDAC as cancer lineages where CEP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP20 survival associations across molecular data types. CEP20 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP20 RNA expression–survival associations across cancer types. High CEP20 expression shows unfavorable associations in SCLC, LGG, BLCA and HNSC, but favorable associations in KIRC and SKCM. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for CEP20 RNA expression.
This table summarizes CEP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CEP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP20 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, KIRP, LIHC and COAD. The KIRC box plot shows higher CEP20 RNA expression in tumor versus normal tissue (log2 FC = +0.691, t-test p < 0.001).
This table shows molecular features associated with CEP20 in patient tissues and cancer cell lines. In patient samples, CEP20 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
